opdp FDA’s OPDP Issues Second Regulatory Action Letter of 2023 By eyeonfda.com Published On :: Wed, 16 Aug 2023 12:05:57 +0000 In what has been a long period of relative low activity, FDA’s OPDP has taken the opportunity to remind us that low enforcement does not mean no enforcement when it comes to promotional speech by pharmaceutical companies. This past June … Continue reading → Full Article FDA Policy Warning Letters #OPDP #pharma #Warning Letters
opdp FDA’s OPDP Issues Third Letter of 2023 By eyeonfda.com Published On :: Tue, 22 Aug 2023 13:20:30 +0000 For the second time this month and the third time this year, FDA’s OPDP has posted notice that it has taken an enforcement action. Last week, a Warning Letter was posted regarding a sales aid. This week it action came … Continue reading → Full Article FDA Policy Warning Letters #FDA #OPDP #pharma
opdp FDA’s OPDP Issues Two New Untitled Letters By eyeonfda.com Published On :: Fri, 10 Nov 2023 07:01:00 +0000 While enforcement has been at a low ebb for quite some time with FDA’s Office of Prescription Drug Promotion (OPDP), this week took a different turn with the posting of two new untitled letters sent October 31. That brings the … Continue reading → Full Article OPDP Regulatory Communications #OPDP #pharma FDA
opdp FDA’s OPDP Sends First Regulatory Letter of the Year Aimed at Rx Drug Promotion By eyeonfda.com Published On :: Mon, 22 Jan 2024 19:39:03 +0000 Last week FDA’s Office of Prescription Drug Promotion issued its first regulatory action letter of the year. This was an Untitled Letter – a/k/a Notice of Violation Letter (NOV) – sent by the agency to Novartis in relation to promotional … Continue reading → Full Article Warning Letters #FDA #OPDP #pharma
